Treatment with betablockers is associated with higher grey-scale median in carotid plaques

Giuseppe Asciutto1*, Nuno V Dias1, Ana Persson2,3, Jan Nilsson2 and Isabel Gonçalves2,3

Abstract

Background: The presence of echolucent carotid plaques as defined by low ultrasound grey-scale median (GSM) is associated with a higher risk of stroke and myocardial infarction. Betablockers have shown possible anti-atherosclerotic effects. The aim of the present study was to determine if there is an association between carotid plaque GSM and treatment with betablockers.

Methods: The GSM of the carotid plaques of 350 patients who underwent carotid endarterectomy (CEA) for asymptomatic (n = 113) or symptomatic (n = 237) carotid disease was measured. Patients were divided in two groups based on the absence/presence of an on-going long-term (i.e. at least 6 months) oral treatment with betablockers at the time of CEA.

Results: The prevalence and type of preoperative neurological symptoms were similar in the two groups. Patients with betablockers had more frequently arterial hypertension (P < .0001), diabetes (P = .035) and a higher BMI (P = .0004), while patients without betablockers were most frequently smokers (P = .017). Patients with betablockers revealed to have higher GSM (37.79 ± 25 vs 32.61 ± 23.50 P = .036). Echogenic plaques (i.e. with GSM > 30) showed to be more frequent in patients with betablockers also after correction for age, gender, the occurrence of preoperative symptoms, diabetes, hypertension, smoking and statins use (P = .024).

Conclusions: These results suggest the use of standardized ultrasound techniques as an important tool in evaluating the effect of anti-atherosclerotic medications and underline the need of further prospective randomized studies on larger patient cohorts in order to confirm these results.

Keywords: Betablockers, Grey-scale median, Carotid artery, Carotid plaque

Background

B-mode ultrasound of the carotid arteries has shown to be a valid method for non-invasive assessment of the presence and clinical burden of atherosclerosis [1,2].

There is today a general consensus that the risk of an atherosclerotic plaque to become symptomatic is not only dependent on the degree of stenosis but also on its composition.

The possibility to assess carotid plaque morphology on ultrasound images in a standardized way has been widely explored in the last decade mostly by the use of the grey-scale median (GSM). Echolucent plaques, which have shown to be rich in lipids and macrophages as expression of a high degree of intrinsic plaque inflammation [3-5].

Treatment with statins has already shown to influence plaque composition and its ultrasound appearance [6,7]. As perioperative beta-blockade became standard therapy in the prevention of cardiovascular (CV) events in patients undergoing vascular surgery, the question about their mechanisms of action was raised. Several hypotheses such that of a reduced inflammatory response which leads to the atherogenic process [8], or the effects by the promotion of laminar flow patterns [9] have been advanced.

Furthermore, betablockers have been shown to have an inhibitory effect on early stages of carotid atherosclerosis development [10,11] and a long-term exposition to betablockers has been associated to a milder degree of inflammation in carotid plaques [12].
The aim of the current study is to investigate the possible influence of long-term treatment with betablockers on the GSM of carotid plaques of patients using it as a surrogate marker of the effects on plaque composition.

Methods

Study population

410 patients who underwent carotid endarterectomy (CEA) between October 2005 and December 2012 at our Vascular Department were identified for inclusion in this study. Informed consent was given by all patients and the study was approved by the local ethical committee (Regional ethical committee, Lund - decision number 472/2005).

Sixty patients were excluded because of the presence of extremely calcified plaques not allowing a GSM measurement, accounting for a total of 350 analysed plaques.

Patients with ipsilateral carotid artery occlusion, radiation carotid artery stenosis or restenosis after previous CEA or endovascular treatment were excluded. An independent accredited neurologist clinically assessed all patients preoperatively. Patients were considered to have asymptomatic disease if they had no amaurosis fugax (AF), transient ischemic attacks (TIAs) or stroke in the 6 months prior to surgery. Indications for surgery were described in detail elsewhere [13].

Information about comorbidities and past medical history were obtained through standardized preoperative interviews and review of the medical records. Comorbidities such as hypertension, diabetes, smoking, as well as the body mass index (BMI), serum levels of triglycerides (TG), low-density lipoproteins (LDL), high-density lipoproteins (HDL) were recorded.

The Swedish national medication register was analysed to identify and determine the presence of any on-going treatment with betablockers at the time of surgery and its duration. This is a nationwide healthcare database where all the prescriptions are registered. Long-term treatment was assumed in patients receiving betablockers of any type and dose for at least six months before surgery, regardless of the primary indication. All patients undergoing CEA were routinely prescribed long-term treatment with statins (simvastatin 40 mg) and acetylsalicylic acid (75 mg) or clopidogrel (75 mg) daily, if this treatment was not already in use.

B-mode ultrasound and measurement of GSM

One day before surgery, carotid ultrasound investigation was performed by a certifies sonographer using an Acuson Sequoia (Acuson, Mountain View, CA, USA) with a 6 MHz-probe according to a previously published method [14].

All images for measurement of GSM in the plaque were obtained in the longitudinal projection showing the largest plaque present. GSM analysis was performed on a longitudinal image showing the largest plaque present in a predefined window consisting of three centimeters of the common carotid artery (CCA), the bulb and one centimeter of the internal- and external carotid artery (ICA and ECA respectively).

A video colour flow sequence was recorded in order to help in outlining the plaque for GSM analysis. All GSM measurements were performed by a single specially trained and experienced sonographer (G.A.) with blinded patient information, including current medications. An intravariability study (n = 20) for measurement of GSM showed that the method had good reproducibility, with a coefficient of variation of 7% and absolute difference between measurements was 1.5 units.

Measurement of GSM was done using Adobe Photoshop 12.0 (Adobe System incorporated, San Jose, CA, USA) with a method previously described [15]. In brief, the method is based on the standardization of images where black, represented by lumen, and white, represented by the adventitia, are given the values 0 and 190, respectively. After linear adjustment of the grey scale in the images according to these values, the plaque was outlined. The median value of the grey scale, the GSM value, in this outlined area was used to define the degree of echogenicity in the plaque.

Statistical analysis

Continuous variables are presented as mean ± standard deviation (SD) when not stated otherwise, while categorical variables are presented as percentages.

As the GSM values of the entire study population were non-normally distributed, its median was used to divide plaques in to echolucent (≤30) and echogenic (>30).

Mann-Whitney U test and Spearman’s rank correlation were used for GSM analysis for the same reason.

Simple and multiple linear regressions were used to explore the relationship between two or more continuous variables, while logistic regression was used in case of dichotomous variables. The regression model included age, gender, hypertension, diabetes, tobacco use, pre-operative symptoms and use of statins. A P-value of <.050 was considered statistically significant. Statistical analysis was performed using SPSS 22.0 (IBM Corp., Amonk, NY: USA).

Results

The plaques of three-hundred and fifty patients (70± 9 years, 245 males) undergoing CEA were included. Two-hundred and thirty seven (68%) plaques were associated with ipsilateral hemispheric symptoms while 113 (32%) were not.

The study population was divided into two subgroups based on the absence (n = 197) or presence (n = 153) of long-term treatment with betablockers at the time of
surgery. Nine different types of beta-blockers were used (metoprolol 72%, atenolol 20%, bisoprolol 4%, others 4%), with a mean time of treatment duration was of 53.2 ± 22.3 months. Overall 87% of the subjects were on statins for at least 1 month before CEA (mean treatment time 46.5 ± 23 months).

As shown in Table 1, patients with betablockers had more frequently arterial hypertension (P < .0001), diabetes (P = .035) and a higher BMI (P = .0004), while patients without betablockers were most frequently smokers (P = .017).

Age, the degree of stenosis, the incidence and type of preoperative neurological symptoms, the time between symptoms and CEA as well as the serum levels of TG, LDL, HDL were not different between the two groups of patients.

As shown in Figure 1, patients with betablockers revealed to have higher GSM than those without (37.79 ± 25 vs 32.61 ± 23.50 P = .036).

Echogenic plaques (i.e. with GSM > 30) were more frequent in patients with betablockers. This finding could be confirmed after regression analysis using age, gender, the occurrence of preoperative symptoms, diabetes, hypertension, smoking, BMI and statins use as confounding factors (see Tables 2, 3, 4, 5).

### Table 1 Demographics

|                          | No beta-blockers (n = 197) | Beta-blockers (n = 153) | P         |
|--------------------------|----------------------------|-------------------------|-----------|
| Age (years)              | 69.91 ± 8.79              | 70.79 ± 8.43            | .364†     |
| Male                     | 69% (137)                 | 71% (108)               | .906*     |
| BMI                      | 25.9 ± 3.3                | 27 ± 3.6                | .0004†    |
| Diabetes                 | 20% (40)                  | 30% (46)                | .035*     |
| Hypertension             | 58% (115)                 | 89% (137)               | < .0001*  |
| Smoking                  |                           |                         |           |
| No                       | 18% (35)                  | 22% (33)                | .017*     |
| Current                  | 37% (73)                  | 23% (35)                |           |
| Ex                       | 45% (89)                  | 56% (85)                |           |
| Statins                  | 85% (167)                 | 89% (136)               | .274*     |
| Degree of stenosis (%)   | 85.6 ± 11.8               | 84.6 ± 12.2             | .3201     |
| Symptoms                 |                           |                         |           |
| Type of symptoms         |                           |                         |           |
| AF                       | 72% (141)                 | 63% (96)                |           |
| TIA                      | 20% (28)                  | 19% (18)                | .6181     |
| Stroke                   | 35% (50)                  | 42% (40)                |           |
| Time to surgery – days   | 25 ± 32.4                 | 21.8 ± 22.6             | .9451     |
| GSM                      | 32.6 ± 23.5               | 37.8 ± 25               | .0361     |

Patients are grouped based on the use of beta-blockers. Categorical variables are presented as percentages with absolute numbers between parenthesis. Continuous variables are presented as mean (standard deviation). AF = amaurosis fugax; BMI = Body mass index; TIA = transient ischemic attack; Time to surgery = time between symptoms (if present) and operation. * = Pearson’s Chi-square; † = Mann-Whitney U test

### Discussion

The main finding of this study was that long-term treatment with betablockers was associated with higher GSM values of carotid plaques. The degree of stenosis and plaque morphology, defined by its structure and surface characteristics, are thought to play an important role in the pathogenesis of CV events. An unstable carotid plaque is associated with a thinning of the fibrous cap, infiltration of inflammatory cells leading to surface ulceration, and plaque rupture [16,17]. An early identification of these features suggesting plaque instability would therefore be very useful for treatment. Recent ultrasound studies based on a computerized measurement of the GSM value of the carotid plaque demonstrated that a low GSM value, reflecting echolucent lesions, was associated with an increased risk of cerebrovascular events and may represent a good predictor of carotid plaque behavior [18], leading to suggest GSM measurement as a complementary tool in the planning of the treatment of carotid artery stenosis in addition to neurological symptoms and the degree of stenosis [19].

The possible anti-atherosclerotic effects of several drugs have been investigated. Statins are probably one of the most studied with its use leading to increased GSM both in carotid and coronary plaques [20,21]. This could be an expression of a more stable plaque phenotype and can be used to monitor their effects on atherosclerotic lesions. Betablockers have been increasingly used in vascular surgery because of their suggested effect in reducing the occurrence of postoperative CV events as suggested by several treatment guidelines [22,23]. However their indiscriminate use in surgical patients, independently of their CV risk, has been strongly questioned [24]. Even if treatment with betablockers has shown to be associated with possible anti-atherosclerotic effects on early stages of carotid lesion development [10,11], their mechanisms of action are still unknown. Their antiatherogenic effects could be the result of the reduced endothelial injury related to a decrease in heart rate and pulse pressure, which produce an increase in shear stress and a decrease in pressure related cycling stretching of the artery [25]. Hampering the sympathetic nervous system could also contribute to the antiatherogenic effects of betablockers preventing endothelial injury and reducing the vessel wall permeability to LDL particles [26]. This results in a milder degree of lipid accumulation that, in its turn, produces a more echogenic plaque pattern on ultrasound [3,27].

A higher degree of intra-plaque inflammation as expressed by a higher content of macrophages [4], and pro-inflammatory cytokines [28] has been shown to lie behind the echolucent aspects of carotid plaques. A possible intrinsic anti-inflammatory action of betablockers, as supported by the results of an animal study [29], could also explain our findings of higher GSM, i.e. more
echogenic plaques in patients on long-term treatment with betablockers.

Several lines of evidence suggest that this could possibly reflect a positive effect on atherosclerotic lesions, which, in turn, are associated with a lower risk for development of clinical events [18,30]. To the best of our knowledge, this is the first study reporting an ultrasound verification of a stabilising effect of the long-term treatment with betablockers on advanced atherosclerotic disease.

As previously reported [12], we could confirm in a larger cohort of patients that those on long-term treatment with betablockers revealed to have more often arterial hypertension, diabetes and a higher BMI. This could suggest a different phenotype than those without, which could be representative of a metabolic syndrome.

A wide range of GSM threshold values, going from 25 to 74, are proposed in the literature to distinguish echolucent from echogenic plaques [18,19,28]. These various cut-off points may be attributable to different choices for the standardization of the reference values (lumen and adventitia). For the purpose of the present study, we decided to use the median GSM value of the entire study cohort as cutoff value (i.e. 30).

Moreover, GSM analysis represents a median value of the whole atherosclerotic area and it may not necessarily reflect the presence of particular regional components. New techniques, such stratified analysis [31] and

Table 2 Simple linear regression analysis

|                                      | B     | St. error | Beta  | t     | P-value |
|--------------------------------------|-------|-----------|-------|-------|---------|
| Age                                  | .174  | .150      | .062  | 1.157 | .248    |
| Gender                               | 3.114 | 2.830     | .059  | 1.100 | .272    |
| BMI                                  | -.291 | .373      | -.042 | -.779 | .437    |
| Preoperative symptoms                | -1.070| .278      | -.021 | -.385 | .700    |
| Diabetes                             | 3.878 | 3.011     | .069  | 1.288 | .199    |
| Hypertension                         | 2.138 | 2.869     | .040  | .745  | .457    |
| Smoking                              |       |           |       |       |         |
| No + Yes 0/Ex 1                      | -1.299| 2.598     | -.027 | -.500 | .617    |
| No + Ex 0/Yes 1                     | 2.561 | 2.810     | .049  | .912  | .363    |
| Statins                              | -1.690| 3.810     | -.024 | -.444 | .658    |
| Betablockers                         | 5.177 | 2.605     | .106  | 1.987 | .048    |

GSM as dependent continuous variable.

Table 3 Multiple linear regression analysis

|                                      | B     | St. error | Beta  | t     | P-value |
|--------------------------------------|-------|-----------|-------|-------|---------|
| Constant                             | 16.698| 19.970    | .840  | .401  |
| Age                                  | .249  | .174      | .089  | 1.430 | .154    |
| Gender                               | 2.830 | 2.907     | .054  | .974  | .331    |
| BMI                                  | -.333 | .399      | -.048 | -.833 | .405    |
| Preoperative symptoms                | -1.693| 2.928     | -.033 | -.578 | .563    |
| Diabetes                             | 3.641 | 3.108     | .065  | 1.171 | .242    |
| Hypertension                         | -1.070| 3.125     | -.013 | -.226 | .821    |
| Smoking                              |       |           |       |       |         |
| No + Yes 0/Ex 1                      | 1.592 | 3.565     | .033  | .447  | .655    |
| No + Ex 0/Yes 1                     | 5.810 | 4.127     | .111  | 1.408 | .160    |
| Statins                              | -1.496| 3.872     | -.021 | -.386 | .699    |
| Betablockers                         | 5.786 | 2.833     | .118  | 2.042 | .042    |

GSM as dependent continuous variable.
ultrasound risk scores [32] have been developed in order to solve this problem, but their application on large scale have been limited by their complexity so far.

The different therapeutic regimes in terms of betablocker type, absolute dose and duration are bringing heterogeneity to the study population, but tend to reflect clinical practice. Furthermore, the small sample size and the predominant use of metoprolol do not allow any meaningful analysis of the possible influence of the drug type on GSM.

Other simultaneous medical treatments, such as statins and immunotherapy [33], as well as the presence of known and unknown comorbidities could have influenced our findings. The association between long-term treatment with betablockers and higher GSM was, nevertheless, confirmed after statistical correction for statins use and the presence of a known hypertension and diabetes. However, the absence of accurate data on blood pressure and HbA1c can be seen as a limitation of this study.

Its non-randomized design is to see as a limitation of this study and should be overcome in order to be able to make general recommendation about the use of a long-term betablockers treatment in patients with advanced atherosclerotic lesions. Furthermore, the retrospective nature of the study with the absence of a GSM measurement upon the initiation of the betablockers treatment does not allow any kind of speculation about their mechanism of action or their possible direct influence on plaque composition. Prospective, randomized studies, above all on patients with asymptomatic carotid disease are therefore required for confirmatory purposes.

| Table 4 Simple logistic regression analysis |
|--------------------------------------------|
|                                  B  | St. error | Wald | P-value | Exp(B) | CI for Exp(B) |
|------------------------------------------|-----------|------|---------|--------|---------------|
| Age                                      | .019      | .013 | .123    | 1.019  | .995 - 1.045  |
| Gender                                   | .568      | .237 | 5.718   | .017   | 1.765 - 2.811 |
| BMI                                       | -.031     | .031 | .984    | .321   | .970 - 1.030  |
| Preoperative symptoms                    | .041      | .229 | .033    | .856   | 1.042 - 1.632 |
| Diabetes                                 | .311      | .250 | 1.547   | .214   | 1.365 - 2.229 |
| Hypertension                             | .341      | .237 | 2.067   | .150   | 1.407 - 2.240 |
| Smoking                                  |           |      |         |        |               |
| No + Yes 0/Ex 1                          | -.413     | -.215| .682    | .055   | .662 - 1.009  |
| No + Ex 0/Yes 1                          | .365      | .233 | 2.443   | .118   | .912 - 2.275  |
| Statins                                  | -.194     | .315 | .378    | .539   | .824 - 1.528  |
| Betablockers                             | .550      | .218 | 6.375   | .012   | 1.734 - 2.657 |

GSM ≤ 30 vs > 30 as dependent categorical variable.

| Table 5 Multiple logistic regression analysis |
|-----------------------------------------------|
|                                  B  | St. error | Wald | P-value | Exp(B) | CI for Exp(B) |
|--------------------------------------------|-----------|------|---------|--------|---------------|
| Constant                                  | -1.871    | 1.738| .253    | .615   | .417 - 1.056  |
| Age                                       | .025      | .015 | 2.785   | .095   | 1.025 - 2.712 |
| Gender                                    | .508      | .250 | 4.131   | .042   | 1.662 - 1.400 |
| BMI                                       | -.029     | .035 | .698    | .403   | .972 - 1.508  |
| Preoperative symptoms                     | -.014     | .250 | .003    | .956   | .986 - 2.513  |
| Diabetes                                  | .291      | .266 | 1.192   | .275   | 1.338 - 2.255 |
| Hypertension                              | .071      | .267 | .071    | .790   | 1.074 - 1.813 |
| Smoking                                   |           |      |         |        |               |
| No + Yes 0/Ex 1                           | -.204     | .303 | .454    | .500   | .815 - 1.476  |
| No + Ex 0/Yes 1                           | .488      | .355 | 1.886   | .170   | 1.629 - 3.267 |
| Statins                                   | -.202     | .330 | .373    | .541   | .817 - 1.561  |
| Betablockers                              | -.643     | .244 | 6.926   | .008   | .526 - 2.325  |

GSM ≤ 30 vs > 30 as dependent categorical variable.
Conclusions
The findings of the current study support the use of standard-ized ultrasound techniques as a means of evaluating the effect of anti-atherosclerotic medications. Moreover, our conclusions suggest other effects of beta-blockers in treating CV diseases beyond hemodynamics. Further studies are needed in order to confirm these results.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
A contributed to the design of the study, the collection of data and their analysis as well as the writing. NVD contributed to the design of the study, the analysis of the data as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing. AP contributed to the analysis as well as the writing. NVD contributed to the design of the study, G A contributed to the design of the study, the collection of data and their analysis as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing. IG contributed to the design of the study, the collection of data and their analysis as well as the writing.

Acknowledgement
The authors thank biostatistician Håkan Lövkvist, Research and Development Centre, Skåne University Hospital, Lund, Sweden, for his assistance in performing the statistical analysis and Gerd Ostling, Cardiovascular Epidemiology Research Group, Skåne University Hospital, Malmö, Sweden for her support in the collection of data. This study was supported by grants from the Swedish Research Council, Marianne and Marcus Wallenberg Foundation, Swedish Heart and Lung Foundation, Hulda Almroth Foundation and the Swedish Foundation for Strategic Research.

Author details
1Vascular Center Malmö-Lund, Skåne University Hospital, Ruth Lundskogs gata 10, 1st floor, Malmö 205 02, Sweden. 2Experimental Cardiovascular Research Unit, Clinical Research Center, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. 3Department of Cardiology, Skåne University Hospital, Malmö, Sweden.

Received: 18 April 2014 Accepted: 26 August 2014
Published: 30 August 2014

References
1. Polak JF, Pencina MJ, Meitsner A, Pencina KM, Brown LS, Wolf PA, D’Agostino RB Sr. Associations of carotid artery intima-media thickness (IMT) with risk factors and prevalent cardiovascular disease: comparison of mean common carotid artery IMT with maximum internal carotid artery IMT. J Ultrasound Med: Offic J Am Inst Ultrasound Med 2010, 29(12):1759–1768.
2. Kawamori R, Tomita H, Ohtsuka N, Inoue A, Kamitani A: Lipid-rich carotid artery plaques appear echolucent on ultrasound. J Vasc Surg 2008, 48(6):1344–1353.
3. Gronholdt ML, Wiebe BM, Laursen H, Nielsen TG, Schroeder TV, Sillehus L: Stabilization of carotid athemomas by quantitative ultrasound analysis in non-hypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005, 46(11):2022–2030.
4. Banfi C, Cavalcà V, Veglia F, Briocchi M, Barcella S, Mussoni L, Boccotti L, Tremoli E, Biglioli P, Agostoni P: Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 2005, 26(9):481–488.
5. Spence JD: Effects of antihypertensive drugs on flow disturbances: nifedipine, captopril, and metoprolol evaluated by quantitative spectral analysis of Doppler flow patterns in patients with carotid stenosis. Clin Invest Med 1994, 17(4):319–325.
6. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G: Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001, 103(13):1721–1726.
7. Wiklund O, Hulte J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke; J Cerebr Circ 2002, 33(2):572–577.
8. Asciutto G, Edsfeldt A, Dias NV, Nilsson J, Prehn C, Adamski J, Goncalves I: Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques. Cardiovasc Pathol: Offic J Soc Cardiovasc Pathol 2013, 22(6):438–443.
9. Asciutto G, Wistrand J, Riva L, Borsse K, Goncalves I, Dias NV: Long-term progression of contralateral carotid artery disease after endarterectomy: Is there a need for Duplex surveillance? Int Angiol. J Int Unio Angiol 2012, 31(4):361–367.
10. Hanssen F, Bergqvist D, Lindblad B, Lindh M, Matzsch T, Lanne T: Accuracy of duplex sonography before carotid endarterectomy—a comparison with angiography. Eur J Vasc Endovasc Surg: Offic J Eur Soc Vasc Surg 1996, 12(3):331–336.
11. Eltozy T, Nicolaidis A, Tegos T, Zarka AZ, Griffin M, Sabaté M: The effect of 8-mode ultrasonic image standardisation on the echodensity of symptomatic and asymptomatic carotid bifurcation plaques, Int Angiol. J Int Unio Angiol 1998, 17(3):179–186.
12. Gollel J, Greenhalgh RM, Davies AH: The symptomatic carotid plaque. Stroke; J Cerebr Circ 2000, 31(3):774–781.
13. Bassiouney HS, Davis H, Massawa N, Gewertz BL, Glogov S, Zarins CK: Critical carotid stenoses: morphologic and chemical similarity between symptomatic and asymptomatic plaques. J Vasc Surg 1989, 9(2):202–212.
14. Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillehus L: Ultrasonic echocarpel carotid plaques predict future strokes. Circulation 2001, 104(1):68–73.
15. Biasi GM, Froio A, Diethrich EB, Deleo G, Galimberti S, Mingazzini P, Nicolaidis AN, Griffin M, Rathel D, Reid DB, Valsecchi MG: Carotid plaque echocellularity increases the risk of stroke in carotid stenting: the imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation 2004, 110(6):756–762.
16. Kadoglou NP, Gerasimidis T, Moumtzouoglou A, Kapelouzou A, Sailer N, Fotiadis G, Vitta J, Katsinis A, Kougias P, Bandonis S, Voliotis K, Karayannacos PE, Lips CD: Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg. Offic J Eur Soc Vasc Surg 2008, 35(5):661–668.
17. Schartl M, Bodisch W, Koschyk DH, Voelker W, Kansch KR, Kreuzer J, Hausmann D, Beckmann S, Gross M. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001, 104(4):387–392.
18. Task Force for Preoperative Cardiac Risk A, Perioperative Cardiac Management in Non-cardiac Surgery. European Society of Cardiology, European Society for Vascular Surgery, European Society of Anaesthesiology. Eur Heart J 2009, 30(22):2769–2782.
19. Fletcher LA, Beckman JA, Brown KA, Calkins H, Chaitman BR, Fleckman LE, Fleckman JM, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF. 2009 ACCF/AHA focused update on perioperative beta blockade included in the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009, 120(16):e169–e276.
24. Group PS, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P: Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008, 371(9627):1839–1847.

25. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128(4):262–269.

26. Kaplan JR, Manuck SB, Adams MR, Weingand KW, Clarkson TB: Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987, 76(6):1364–1372.

27. Goncalves I, Lindholm MW, Pedro LM, Dias N, Fernandes e Fernandes J, Fredrikson GN, Nilsson J, Moses J, Ares MP: Elastin and calcium rather than collagen or lipid content are associated with echogenicity of human carotid plaques. Stroke; J Cerebr Circ 2004, 35(12):2795–2800.

28. Goncalves I, Moses J, Pedro LM, Dias N, Fernandes e Fernandes J, Nilsson J, Ares MP: Echolucency of carotid plaques correlates with plaque cellularity. Eur J Vasc Endovasc Surg: Offic J Eur Soc Vasc Surg 2003, 26(1):32–38.

29. Pettersson K, Bjork H: Inhibition of platelet accumulation by beta 1-adrenoceptor blockade in the thoracic aorta of rabbits subjected to experimental sympathetic activation. Cardiovasc Drugs Ther/Sponsored Int Soc Cardiovasc Pharmacother 1992, 6(5):505–511.

30. Mathiesen EB, Bonaa KH, Joakimsen O: Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 2001, 103(17):2171–2175.

31. Sztafzel R, Momjian-Mayor I, Comelli M, Momjian S: Correlation of cerebrovascular symptoms and microembolic signals with the stratified gray-scale median analysis and color mapping of the carotid plaque. Stroke; J Cerebr Circ 2006, 37(3):824–829.

32. Pedro LM, Fernandes e Fernandes J, Pedro MM, Goncalves I, Dias NV, Fernandes e Fernandes R, Cameiro TF, Balsinha C: Ultrasoundographic risk score of carotid plaques. Eur J Vasc Endovasc Surg: Offic J Eur Soc Vasc Surg 2002, 24(6):492–498.

33. Morgan T, Anderson A: The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 2003, 5(1):53–57.